CoChat

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis

Open access

Published version of a preprint

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Patients with anaplastic lymphoma kinase (ALK)–driven neuroblastoma may respond to tyrosine kinase inhibitors, but resistance to treatment occurs and methods currently used for detection of residual disease have limited sensitivity. Here, we present a national unselected cohort of five patients with relapsed or refractory ALK-driven neuroblastoma treated with lorlatinib as monotherapy and test the potential of targeted circulating tumor DNA (ctDNA) analysis as a guide for treatment decisions in these patients. We developed a sequencing panel for ultrasensitive detection of ALK mutations associated with neuroblastoma or resistance to tyrosine kinase inhibitors and used it for ctDNA analysis in 83 plasma samples collected longitudinally from the four patients who harbored somatic ALK mutations. All four patients with ALK p.R1275Q experienced major responses and were alive 35 to 61 months after starting lorlatinib. A fifth patient with ALK p.F1174L initially had a partial response but relapsed after 10 months of treatment. In all cases, ctDNA was detected at the start of lorlatinib single-agent treatment and declined gradually, correlating with clinical responses. In the two patients exhibiting relapse, ctDNA increased 9 and 3 months, respectively, before clinical detection of disease progression. In one patient harboring HRAS p.Q61L in the relapsed tumor, retrospective ctDNA analysis showed that the mutation appeared de novo after 8 months of lorlatinib treatment. We conclude that some patients with relapsed or refractory high-risk neuroblastoma show durable responses to lorlatinib as monotherapy, and targeted ctDNA analysis is effective for evaluation of treatment and early detection of relapse in ALK-driven neuroblastoma. Significance: We present five patients with ALK-driven relapsed or refractory neuroblastoma treated with lorlatinib as monotherapy. All patients responded to treatment, and four of them were alive after 3 to 5 years of follow-up. We performed longitudinal ctDNA analysis with ultra-deep sequencing of the ALK tyrosine kinase domain. We conclude that ctDNA analysis may guide treatment decisions in ALK-driven neuroblastoma, also when the disease is undetectable using standard clinical methods.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2767-9764.crc-24-0338

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Clinical response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma. Black arrows denote ongoing treatment or follow-up. *Germline ALK variant. CR, complete response; PR partial response.
Figure 1 Clinical response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma. Black arrows denote ongoing treatment or follow-up. *Germline ALK variant. CR, complete response; PR partial response.CC BY · PubMed Central
Figure 2 ctDNA analysis using the NB-ALK sequencing panel. Pink areas denote parts of the ALK gene included in the panel. Recurrent mutations previously detected in neuroblastoma or associated with resistance to TKIs that are covered by the panel are shown; neuroblastoma hotspot mutations are bold. Angled numbers denote the range of ALK amino acid positions covered by each of the seven assays.
Figure 2 ctDNA analysis using the NB-ALK sequencing panel. Pink areas denote parts of the ALK gene included in the panel. Recurrent mutations previously detected in neuroblastoma or associated with resistance to TKIs that are covered by the panel are shown; neuroblastoma hotspot mutations are bold. Angled numbers denote the range of ALK amino acid positions covered by each of the seven assays.CC BY · PubMed Central
Figure 3 Lasting response to lorlatinib in a patient (patient 1) with relapsed neuroblastoma harboring ALK p.R1275Q. A, Chest computed tomography (top) and MIBG scans (bottom) at time of initial diagnosis, at relapse, and after 2 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA during and after lorlatinib treatment. ND, not detected. C, Chromogranin A. URL, upper reference limit (102 µg/L). NSE, urine VMA and urine HVA were within normal ranges at time of relapse and were therefore not further analyzed. HVA, homovanillic acid; VMA, vanillylmandelic acid.
Figure 3 Lasting response to lorlatinib in a patient (patient 1) with relapsed neuroblastoma harboring ALK p.R1275Q. A, Chest computed tomography (top) and MIBG scans (bottom) at time of initial diagnosis, at relapse, and after 2 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA during and after lorlatinib treatment. ND, not detected. C, Chromogranin A. URL, upper reference limit (102 µg/L). NSE, urine VMA and urine HVA were within normal ranges at time of relapse and were therefore not further analyzed. HVA, homovanillic acid; VMA, vanillylmandelic acid.CC BY · PubMed Central
Figure 4 Detection of relapse with ctDNA analysis 9 months prior to clinical presentation in a patient (patient 2) with ALK p.R1275Q-positive neuroblastoma treated with lorlatinib. A, MIBG scans. B, Levels of ctDNA. C, NSE. CS, Curie score; ND, not detected; TID, temozolomide, irinotecan and dinutuximab; URL, upper reference limit (16.3 µg/L).
Figure 4 Detection of relapse with ctDNA analysis 9 months prior to clinical presentation in a patient (patient 2) with ALK p.R1275Q-positive neuroblastoma treated with lorlatinib. A, MIBG scans. B, Levels of ctDNA. C, NSE. CS, Curie score; ND, not detected; TID, temozolomide, irinotecan and dinutuximab; URL, upper reference limit (16.3 µg/L).CC BY · PubMed Central
Figure 5 Long-term response to lorlatinib in a patient (patient 4) with refractory ALK p.R1275Q-positive neuroblastoma. A, MIBG or 68Ga-DOTATATE scans at the time of diagnosis, after induction of chemotherapy, and after 5 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA. C, Plasma methoxy noradrenaline. ND, not detected; URL, upper reference limit (0.7 nmol/L).
Figure 5 Long-term response to lorlatinib in a patient (patient 4) with refractory ALK p.R1275Q-positive neuroblastoma. A, MIBG or 68Ga-DOTATATE scans at the time of diagnosis, after induction of chemotherapy, and after 5 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA. C, Plasma methoxy noradrenaline. ND, not detected; URL, upper reference limit (0.7 nmol/L).CC BY · PubMed Central
Figure 6 Early detection of relapse and emergence of an HRAS p.Q61L mutation during lorlatinib treatment in a patient (patient 5) with ALK p.F1174L-positive neuroblastoma. A, MIBG scans at initial diagnosis, at the first relapse, after 4 months of lorlatinib (partial response), and at second relapse after 10.5 months of lorlatinib treatment. B, Allele frequency of HRAS p.Q61L in tumor tissue at different time points. C, Levels of ctDNA. D, Clinical tumor markers, values are normalized to the upper reference limit (URL) for each marker. CGA, chromogranin A; Lorla, lorlatinib; ND, not detected.
Figure 6 Early detection of relapse and emergence of an HRAS p.Q61L mutation during lorlatinib treatment in a patient (patient 5) with ALK p.F1174L-positive neuroblastoma. A, MIBG scans at initial diagnosis, at the first relapse, after 4 months of lorlatinib (partial response), and at second relapse after 10.5 months of lorlatinib treatment. B, Allele frequency of HRAS p.Q61L in tumor tissue at different time points. C, Levels of ctDNA. D, Clinical tumor markers, values are normalized to the upper reference limit (URL) for each marker. CGA, chromogranin A; Lorla, lorlatinib; ND, not detected.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 15

Metadata

Authors
Ek, T., Ibrahim, R. R., Vogt, H., Georgantzi, K., Träger, C., Gaarder, J., Djos, A., Rahmqvist, I., Mellström, E., Pujol-Calderón, F., Vannas, C., Hansson, L., Fagman, H., Treis, D., Fransson, S., Österlund, T., Chuang, T.-P., Verhoeven, B. M., Ståhlberg, A., Palmer, R. H., Hallberg, B., Martinsson, T., Kogner, P., & Dalin, M.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Wallenberg Centre for Molecular and Translational Medicine (SE)
  • Linköping University (SE)
  • Karolinska University Hospital (SE)
  • Uppsala University (SE)
  • University of Gothenburg (SE)
  • Karolinska Institutet (SE)
Corresponding author
Dalin, Martin
Venue
Cancer Research Communications
Published
2024-09-01
Volume
4
Issue
9
Pages
2553-2564
ISSN
2767-9764 (ISSN-L)
OpenAlex
W4401815780
Cited by
15
References
46
Citations by year
2026: 9 · 2025: 5 · 2024: 1
FWCI
4.01
Type
journal article
Language
en
Open access
Locations
  • Cancer Research Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Diva portal (Dalarna University Library) (submittedVersion, other-oa)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
Keywords
lorlatinib, circulating tumor DNA, liquid biopsy, tyrosine kinase inhibitor resistance, early relapse detection, ultra-deep sequencing, longitudinal ctDNA monitoring, treatment response monitoring
MeSH terms
Circulating Tumor DNA, Anaplastic Lymphoma Kinase, Aminopyridines, Child, Child, Preschool, Female, Humans, Infant, Lactams, Male, Mutation, Neoplasm Recurrence, Local, Neuroblastoma, Pyrazoles, Treatment Outcome, Drug Resistance, Neoplasm, Lactams, Macrocyclic, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis. https://app.cochat.ai/papers/10.1158/2767-9764.crc-24-0338
The paper
Ek, T., Ibrahim, R. R., Vogt, H., Georgantzi, K., Träger, C., Gaarder, J., Djos, A., Rahmqvist, I., Mellström, E., Pujol-Calderón, F., Vannas, C., Hansson, L., Fagman, H., Treis, D., Fransson, S., Österlund, T., Chuang, T.-P., Verhoeven, B. M., Ståhlberg, A., . . . Dalin, M. (2024). Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-24-0338

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.